Cellebrite DI Ltd Ordinary Shares CLBT 深 沪
交易中 08-01 11:52:09 美东时间
13.74
-0.240
-1.72%
华盛通- 最 高13.92
- 今 开13.84
- 成交量 41.80万股
- 最 低 13.5136
- 昨 收 13.98
- 总市值 32.84亿
- 52周最高 26.30
- 市盈率 静 --
- 换手率 0.17%
- 52周最低 13.19
- 委 比 60.00%
- 总股本 2.39亿
- 历史最高 26.30
- 量 比 1.15
- 振 幅 2.91%
- 历史最低 3.80
- 每 手 1
- 风险率 2.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多U.S. Department of Justice to Sponsor Cellebrite for FedRAMP ATO
Cellebrite announced U.S. Department of Justice (DOJ) sponsorship to advance its Cellebrite Government Cloud (CGC) from FedRAMP High Ready to "In Process" status, a key step toward full Authorization to Operate (ATO). CGC will offer secure, cutting-edge cloud solutions, including Cellebrite Inseyets and Guardian, enhancing investigative workflows and operational efficiency for U.S. federal agencies.
07-23 12:30
Cellebrite Appoints David Barter as New CFO
The latest update is out from Cellebrite DI ( ($CLBT) ). Cellebrite announced t...
07-08 21:17
Cellebrite Names David Barter Chief Financial Officer
Cellebrite announced the appointment of David Barter as its new Chief Financial Officer, succeeding Dana Gerner, who is retiring after 11 years in the role. Barter brings over 30 years of experience in scaling global software companies, most recently at New Relic, where he helped drive growth to nearly $1 billion in annual revenue. Gerner will remain in an advisory role until the company reports its second-quarter 2025 financial results. Barter w...
07-08 12:30
Accelerating Child Exploitation Investigations: Cellebrite Integrates Data from the National Center for Missing and Exploited Children (NCMEC)
Cellebrite has expanded its partnership with the National Center for Missing and Exploited Children (NCMEC) by integrating NCMEC's CyberTipline hash value list into its Cellebrite Insight digital forensics software. This integration enables investigators to quickly identify known child sexual abuse material (CSAM) files, accelerating investigations and protecting victims. The hash value list includes approximately 10 million confirmed CSAM files ...
06-24 20:01
美股大行评级 | 潜在涨幅925.64%！Aemetis获Ascendiant Capital升目标价至20美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1138028221594226688.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Aemetis(AMTX)"买入"评级，目标价从19美元升至20美元</p> <p>• Ascendiant Capital：维持Lucid Diagnostics(LUCD)"买
06-07 08:37
Needham Reiterates Buy on Cellebrite DI, Maintains $24 Price Target
Needham analyst Mike Cikos reiterates Cellebrite DI (NASDAQ:CLBT) with a Buy and maintains $24 price target.
06-06 19:16
Cellebrite Agrees To Acquire Corellium For Enterprise Value Of $170M In Cash With $20M Converted To Equity At Closing
Cellebrite (NASDAQ:CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced its agreement to acquire Corellium, a leader in Arm-based virtualization software.
06-05 19:32
Cellebrite to Acquire Corellium
Cellebrite has agreed to acquire Corellium for $170 million in cash, enhancing its digital investigation and smart device security capabilities. The deal combines Cellebrite's digital investigative solutions with Corellium's Arm-based virtualization technology, benefiting public safety, defense, and private sectors. The acquisition is expected to expand Cellebrite's market reach and strengthen its offerings in mobile vulnerability research, secur...
06-05 11:30
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
